



FOR IMMEDIATE RELEASE

LMA BUILDS DISTRIBUTION NETWORK FOR UROLOGY BUSINESS

Appoints exclusive distributor for LMA StoneBreaker™ in France

Singapore, 28 March 2007 – Mainboard-listed LMA International NV (SGX: LMA), the global leader in the development and marketing of the LMA™ laryngeal mask airway range of supraglottic airway management devices, announced that its subsidiary LMA Urology Suisse S.A. has entered into a distribution agreement with EDAP TMS S.A. ("EDAP") to exclusively distribute its innovative lithotripsy device LMA StoneBreaker™ in France.

EDAP, with more than 25 years of experience in sales and distribution, has a strong knowledge of the medical community in France. The company has significant expertise in the domestic lithotripsy market and a dedicated distribution network.

Paul Molloy, President of LMA Urology Suisse S.A., said, "LMA is very excited to be working with EDAP in France where it is widely recognized as a pioneering and innovative market leader in the distribution of innovative urinary medical systems. We are confident that the addition of our LMA StoneBreaker™ device to the EDAP portfolio will benefit both companies and bring a new standard of care to those suffering from kidney stones."

Marc Oczachowski, Chief Operating Officer of EDAP, added, "We are pleased to work with LMA to introduce the StoneBreaker™ in France. EDAP has proved its ability to bring new therapeutic devices to market and today benefits from a strong customer base and a supportive medical network, which makes us confident of a successful launch for the LMA StoneBreaker™."

The LMA StoneBreaker™ is a portable intra-corporeal contact lithotripter which effectively fragments stones in the urinary tract. This handheld system complements lithotripsy procedures performed with extracorporeal shock wave lithotripsy devices by targeting stones located in places which cannot be reached with an extra-corporeal shockwave generator. The LMA StoneBreaker™, manufactured in Switzerland, received the CE mark in June 2006 and is validated by extensive clinical trials confirming the effectiveness of this device.

- Ends -

For media queries, please contact:

Gavin Anderson & Company, Tel: +65 6339 9110

Sharon Seetho, Tel: +65 9009 8495

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

About LMA

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Bonn, Germany, San Diego, California and Melbourne, Australia. Through its 50 percent joint venture in LMA Urology Limited, the Group has a subsidiary in Gland, Switzerland to design, manufacture and distribute the LMA StoneBreaker™.

Incorporated in the Netherlands Antilles in 1998, LMA listed on the Mainboard of the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ laryngeal mask airway range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ laryngeal mask airway as an alternative airway management device. LMA has established a leading position in this growing market.

DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.